Document and Entity Information |
Sep. 15, 2022 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001556263 |
| Document Type | 8-K/A |
| Document Period End Date | Sep. 15, 2022 |
| Entity Registrant Name | Syros Pharmaceuticals, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-37813 |
| Entity Tax Identification Number | 45-3772460 |
| Entity Address, Address Line One | 35 CambridgePark Drive |
| Entity Address, Address Line Two | 4th Floor |
| Entity Address, City or Town | Cambridge |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02140 |
| City Area Code | (617) |
| Local Phone Number | 744-1340 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | SYRS |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | On September 15, 2022, Syros Pharmaceuticals, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a Current Report on Form 8-K (the “Original Form 8-K”) to report, among other things, the voting results of the proposals submitted to the Company’s stockholders at a special meeting of stockholders held on September 15, 2022 (the “Special Meeting”). This Amendment No. 1 to the Original Form 8-K (“Amendment No. 1”) is being filed to correct certain errors by third party proxy intermediaries with respect to the reporting of the voting results. Correction of these errors did not change the outcome of any of the matters voted on. This Amendment No. 1 amends and restates the disclosure provided under Item 5.07 of the Original Form 8-K in its entirety. |